Abstract
The older adult asthmatic population is increasing, as is the complexity of asthma treatments. This segment of asthmatics has been understudied, and modalities of therapy are affected by the aging process and comorbid diseases. Corticosteroids are the mainstay of emergency care and of chronic persistent asthma care. Inhaled bronchodilators have proven effective both in the acute setting and as an add-on therapy for chronic control. Leukotriene inhibitors have value especially where inhaler techniques are problematic. Theophylline has bronchodilator and potentially anti-inflammatory effects but requires close monitoring of drug levels. Specific allergen immunotherapy using both subcutaneous and sublingual routes of administration may have value in disease modification but requires further evaluation in the older adult. Biological therapies are available for severe asthma but require further controlled studies in older adults. Complementary medical methodologies are commonly used by patients but not adequately evaluated for efficacy or safety in older adults. Vaccines and good adherence measures are essential due to the polypharmacy and comorbidities inherent to an older adult population.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Battaglia S, Benfante A, Scichilone N. Asthma in the older adult: presentation, considerations and clinical management. Expert Rev Clin Immunol. 2015;11(12):1297–308.
Battaglia S, et al. Are asthmatics enrolled in randomized trials representative of real-life outpatients? Respiration. 2015;89(5):383–9.
Dunn RM, Busse PJ, Wechsler ME. Asthma in the elderly and late-onset adult asthma. Allergy. 2018;73(2):284–94.
Bellanti JA, Settipane RA. Atopy, asthma, and the elderly: a paradigm for personalized therapy. Allergy Asthma Proc. 2017;38(3):167–9.
Godinho Netto AC, et al. Fraction of exhaled nitric oxide measurements in the diagnoses of asthma in elderly patients. Clin Interv Aging. 2016;11:623–9.
Scichilone N, et al. Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly. Clin Mol Allergy. 2015;13(1):7.
Horak F, et al. Diagnosis and management of asthma – statement on the 2015 GINA guidelines. Wien Klin Wochenschr. 2016;128(15–16):541–54.
Spaggiari L, et al. Exacerbations of severe asthma: a focus on steroid therapy. Acta Biomed. 2014;85(3):205–15.
Lefebvre P, et al. Burden of systemic glucocorticoid-related complications in severe asthma. Curr Med Res Opin. 2017;33(1):57–65.
Baptist AP, Busse PJ. Asthma over the age of 65: all’s well that ends well. J Allergy Clin Immunol Pract. 2018;6(3):764–73.
Kim MY, Song WJ, Cho SH. Pharmacotherapy in the management of asthma in the elderly: a review of clinical studies. Asia Pac Allergy. 2016;6(1):3–15.
Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(4):580–4.
Busse PJ, et al. Effect of aging on sputum inflammation and asthma control. J Allergy Clin Immunol. 2017;139(6):1808–1818 e6.
Slavin RG, et al. Asthma in older adults: observations from the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study. Ann Allergy Asthma Immunol. 2006;96(3):406–14.
Hartert TV, et al. Underutilization of controller and rescue medications among older adults with asthma requiring hospital care. J Am Geriatr Soc. 2000;48(6):651–7.
Dunn RM, et al. Impact of age and sex on response to asthma therapy. Am J Respir Crit Care Med. 2015;192(5):551–8.
Hira D, et al. Problems of elderly patients on inhalation therapy: difference in problem recognition between patients and medical professionals. Allergol Int. 2016;65(4):444–9.
Melani AS, et al. Time required to rectify inhaler errors among experienced subjects with faulty technique. Respir Care. 2017;62(4):409–14.
Ishiura Y, et al. A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in elderly asthmatics. Drug Res (Stuttg). 2018;68(1):38–44.
Turan O, Turan PA, Mirici A. Parameters affecting inhalation therapy adherence in elderly patients with chronic obstructive lung disease and asthma. Geriatr Gerontol Int. 2017;17(6):999–1005.
Hirose M, et al. Sex differences in use of inhalants by elderly patients with asthma. Clin Interv Aging. 2015;10:1305–10.
Serper M, et al. Health literacy, cognitive ability, and functional health status among older adults. Health Serv Res. 2014;49(4):1249–67.
Park HW, et al. Prediction of asthma exacerbations in elderly adults: results of a 1-year prospective study. J Am Geriatr Soc. 2013;61(9):1631–2.
Zhou W, Ke H, Li Y. Effect of nebulized corticosteroids on long-term poorly controlled asthma in elderly patients. Chin J Geriatr. 2015;34(7):711–4.
Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123(11):1001–6.
Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA. 1998;280(6):539–43.
Ernst P, et al. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J. 2006;27(6):1168–74.
Leone FT, et al. Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma: collaboration of American College of Chest Physicians, American Academy of Allergy, Asthma, and Immunology, and American College of Allergy, Asthma, and Immunology. Chest. 2003;124(6):2329–40.
Kagohashi K, et al. Long-term safety of budesonide/formoterol for the treatment of elderly patients with bronchial asthma. Exp Ther Med. 2014;7(4):1005–9.
Gupta P, O’Mahony MS. Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: recommendations for prescribing. Drugs Aging. 2008;25(5):415–43.
Bellia V, et al. Asthma in the elderly: mortality rate and associated risk factors for mortality. Chest. 2007;132(4):1175–82.
Connolly MJ. Ageing, late-onset asthma and the beta-adrenoceptor. Pharmacol Ther. 1993;60(3):389–404.
Connolly MJ, et al. Impaired bronchodilator response to albuterol in healthy elderly men and women. Chest. 1995;108(2):401–6.
Chauhan BF, Ducharme FM. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev. 2014;1:CD003137.
O’Byrne PM, et al. Increasing doses of inhaled corticosteroids compared to adding long-acting inhaled beta2-agonists in achieving asthma control. Chest. 2008;134(6):1192–9.
Stanford RH, et al. Effect of combination fluticasone propionate and salmeterol or inhaled corticosteroids on asthma-related outcomes in a medicare-eligible population. Am J Geriatr Pharmacother. 2012;10(6):343–51.
Cates CJ, et al. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev. 2013;6:CD006924.
Cates CJ, et al. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev. 2013;3:CD006922.
Rodrigo GJ, Rodrigo C. First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department. Am J Respir Crit Care Med. 2000;161(6):1862–8.
Sobieraj DM, et al. Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma: a systematic review and meta-analysis. JAMA. 2018;319(14):1473–84.
Slawson D. Long-acting muscarinic antagonists plus inhaled steroids is equal to long-acting beta-agonists plus inhaled steroids. Am Fam Physician. 2018;98(8).: Online
Kerstjens HA, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367(13):1198–207.
Peters SP, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010;363(18):1715–26.
Magnussen H, et al. Improvements with tiotropium in COPD patients with concomitant asthma. Respir Med. 2008;102(1):50–6.
Tashkin DP, et al. Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT(R) trial. Respir Res. 2015;16:65.
Korenblat PE, et al. Effect of age on response to zafirlukast in patients with asthma in the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT). Ann Allergy Asthma Immunol. 2000;84(2):217–25.
Creticos P, et al. Loss of response to treatment with leukotriene receptor antagonists but not inhaled corticosteroids in patients over 50 years of age. Ann Allergy Asthma Immunol. 2002;88(4):401–9.
Trinh HK, et al. Leukotriene receptor antagonists for the treatment of asthma in elderly patients. Drugs Aging. 2016;33(10):699–710.
Ye YM, et al. Addition of montelukast to low-dose inhaled corticosteroid leads to fewer exacerbations in older patients than medium-dose inhaled corticosteroid monotherapy. Allergy Asthma Immunol Res. 2015;7(5):440–8.
Bozek A, et al. Montelukast as an add-on therapy to inhaled corticosteroids in the treatment of severe asthma in elderly patients. J Asthma. 2012;49(5):530–4.
Columbo M. Asthma in the elderly: a double-blind, placebo-controlled study of the effect of montelukast. Asthma Res Pract. 2017;3:3.
Spears M, et al. Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: a pilot study. Eur Respir J. 2009;33(5):1010–7.
Barnes PJ. Theophylline. Am J Respir Crit Care Med. 2013;188(8):901–6.
Ohta K, et al. A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD. Respir Med. 2004;98(10):1016–24.
Verma P, Randhawa I, Klaustermeyer WB. Clinical efficacy of omalizumab in an elderly veteran population with severe asthma. Allergy Asthma Proc. 2011;32(5):346–50.
Garcia G, et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest. 2013;144(2):411–9.
de Llano LP, Vennera Mdel C, Alvarez FJ, Medina JF, Borderdas L, Pellicer C, Gonzalez H, Gullon JA, Martinez-Moragon E, Sabadell C, Zamarro S, Picado C. Effects of omalizumab in non-atopic asthma; results froma a Spanish multicenter registry. J Asthma. 2013;144:411–9.
Song WJ, et al. Staphylococcal enterotoxin sensitization in a community-based population: a potential role in adult-onset asthma. Clin Exp Allergy. 2014;44(4):553–62.
Song WJ, et al. Staphylococcal enterotoxin IgE sensitization in late-onset severe eosinophilic asthma in the elderly. Clin Exp Allergy. 2016;46(3):411–21.
Bachert C, Gevaert P, van Cauwenberge P. Staphylococcus aureus enterotoxins: a key in airway disease? Allergy. 2002;57(6):480–7.
Tversky JR, et al. Human blood dendritic cells from allergic subjects have impaired capacity to produce interferon-alpha via Toll-like receptor 9. Clin Exp Allergy. 2008;38(5):781–8.
Maykut RJ, Kianifard F, Geba GP. Response of older patients with IgE-mediated asthma to omalizumab: a pooled analysis. J Asthma. 2008;45(3):173–81.
Yalcin AD, et al. Omalizumab (anti-IgE) therapy increases blood glucose levels in severe persistent allergic asthma patients with diabetes mellitus: 18 month follow-up. Clin Lab. 2014;60(9):1561–4.
de Roos EW, et al. Targeted therapy for older patients with uncontrolled severe asthma: current and future prospects. Drugs Aging. 2016;33(9):619–28.
Bernstein DI, Mansfield L, Zangrilli J, Garin M. Efficacy of reslizumab in older patients (> 65 years) with asthma and elevated blood eosinophils: results from a pooled analysis of two phase 3, placebo-controlled trials. J Allergy Clin Immunol. 2016;137(2):AB86.
Brusselle GG, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013;68(4):322–9.
Brusselle G, et al. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinohils. Pulm Pharmacol Ther. 2017;43:39–45.
Wenzel S, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44.
Dupixent (dupilumb) injection 200 mg. 300mg Full Prescribing, S. Genzyme, editor; 2018.
Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults. N Engl J Med. 2017;377(10):965–76.
Cox L, Nelson H, Lockey R. Allergen immunotherapy: a practice parameter. J Allergy Clin Immunol. 2011;127(1)(3rd update): 51–55.
Lang DM. Do beta-blockers really enhance the risk of anaphylaxis during immunotherapy? Curr Allergy Asthma Rep. 2008;8(1):37–44.
Marogna M, et al. Sublingual immunotherapy for allergic respiratory disease in elderly patients: a retrospective study. Eur Ann Allergy Clin Immunol. 2008;40(1):22–9.
Bozek A, et al. Grass pollen sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with seasonal allergic rhinitis. Am J Rhinol Allergy. 2014;28(5):423–7.
Canonica GW, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7(1):6.
Emminger W, et al. The SQ house dust mite SLIT-Tablet is well tolerated in patients with house dust mite respiratory allergic disease. Int Arch Allergy Immunol. 2017;174(1):35–44.
Albert RK, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–98.
Kew KM, et al. Macrolides for chronic asthma. Cochrane Database Syst Rev. 2015;9:CD002997.
Simpson JL, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2008;177(2):148–55.
Cameron EJ, Chaudhuri R, Mair F, McSharry C, Greenlaw N, Weir CJ, et al. Randomized controlled trial of azithomycin in smokers with asthma. Eur Respir J. 2013;42(5):1412–5.
Burn J, et al. Procedural and short-term safety of bronchial thermoplasty in clinical practice: evidence from a national registry and Hospital Episode Statistics. J Asthma. 2017;54(8):872–9.
Torrego A, et al. Bronchial thermoplasty for moderate or severe persistent asthma in adults. Cochrane Database Syst Rev. 2014;3:CD009910.
Wechsler ME, et al. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N Engl J Med. 2011;365(2):119–26.
Nielsen NH, et al. Chronic asthma and chiropractic spinal manipulation: a randomized clinical trial. Clin Exp Allergy. 1995;25(1):80–8.
Balon J, et al. A comparison of active and simulated chiropractic manipulation as adjunctive treatment for childhood asthma. N Engl J Med. 1998;339(15):1013–20.
Huntley A, White AR, Ernst E. Relaxation therapies for asthma: a systematic review. Thorax. 2002;57(2):127–31.
Hackman RM, Stern JS, Gershwin ME. Hypnosis and asthma: a critical review. J Asthma. 2000;37(1):1–15.
Reilly D, et al. Is evidence for homoeopathy reproducible? Lancet. 1994;344(8937):1601–6.
Lewith GT, et al. Use of ultramolecular potencies of allergen to treat asthmatic people allergic to house dust mite: double blind randomised controlled clinical trial. BMJ. 2002;324(7336):520.
Bielory L. Adverse reactions to complementary and alternative medicine: ragweed’s cousin, the coneflower (echinacea), is “a problem more than a sneeze”. Ann Allergy Asthma Immunol. 2002;88(1):7–9.
Vliagoftis H, et al. Probiotics for the treatment of allergic rhinitis and asthma: systematic review of randomized controlled trials. Ann Allergy Asthma Immunol. 2008;101(6):570–9.
Acknowledgments
Rebecca A Goldberg RN, BS Acct., Barbara A. Gushrowski, MLS, Manager of Library Services at Community Health Network, Indianapolis, Indiana.
Potential Conflicts of Interest
Consultant and or Speaker for AstraZeneca, Genentech, Boehringer Ingelheim, Circassia, Shire.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Goldberg, P. (2019). Medication Efficacy and Side Effects in Older Asthmatics. In: Epstein, T., Nyenhuis, S. (eds) Treatment of Asthma in Older Adults. Springer, Cham. https://doi.org/10.1007/978-3-030-20554-6_6
Download citation
DOI: https://doi.org/10.1007/978-3-030-20554-6_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-20553-9
Online ISBN: 978-3-030-20554-6
eBook Packages: MedicineMedicine (R0)